Independent Financial Group LLC Takes Position in Gilead Sciences, Inc. $GILD

Independent Financial Group LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 9,273 shares of the biopharmaceutical company’s stock, valued at approximately $1,292,000.

Other large investors also recently bought and sold shares of the company. Paulson Wealth Management Inc. grew its holdings in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 67 shares during the period. Essex Financial Services Inc. lifted its holdings in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the last quarter. Davidson Trust Co. lifted its holdings in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the last quarter. Alpha Cubed Investments LLC boosted its position in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 75 shares in the last quarter. Finally, Personal CFO Solutions LLC boosted its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 76 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Truist Financial dropped their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Royal Bank Of Canada cut their target price on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Wednesday, May 20th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Stock Down 0.8%

Gilead Sciences stock opened at $133.21 on Tuesday. The firm has a market cap of $165.39 billion, a price-to-earnings ratio of 18.15 and a beta of 0.32. The stock has a fifty day simple moving average of $129.72 and a two-hundred day simple moving average of $135.37. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company posted $1.81 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is 44.69%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 77,000 shares of company stock worth $9,978,740. Company insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.